THE EFFECTS OF ALLOFERON (ALLOKIN) IN THE THERAPY OF METABOLIC SYNDROME (A PILOT STUDY)

N A Didkovsky; I K Malashenkova; J V Abakumova; D P Ogurtsov; S A Krynskiy; N A Hailov; E I Chekulaeva; M V Mamoshina

Medical academic journal ›› 2019, Vol. 19 ›› Issue (1S) :212 -215.

Articles

oration

THE EFFECTS OF ALLOFERON (ALLOKIN) IN THE THERAPY OF METABOLIC SYNDROME (A PILOT STUDY)

Author information +

History +

Abstract

The aim of this work was to study the influence of treatment with alloferon (allocin) in combination with pyrogenal and cytokine therapy on the parameters of immunity, systemic inflammation, levels of herpesvirus replication and biochemical profile of patients with metabolic syndrome to search for new approaches to the treatment of the early stages of the disease. Markers of systemic inflammation and immunity, including key cytokines and lymphocyte subpopulations, were investigated. It was found that 1 month after the start of the study in patients receiving only allokin, there were signs of activation of humoral immunity. In patients receiving complex therapy, there were signs of activation of the cell-mediated mechanisms of adaptive immunity. These changes persisted after 6 months and were not accompanied by signs of systemic inflammation when evaluated at 1 and 6 months. The results of further observation showed that in patients receiving complex therapy, there were positive changes in lipid profile, which were the most prominent at the end of the study. Thus, in this study it was shown that in patients with metabolic syndrome complex immunomodulatory therapy, including allokin, pirogenal, ingaron and Roncoleukin, led to the activation of the cellular link of adaptive immunity, without causing a long-term increase in the level of markers of systemic inflammatory response. During long term observation the patients had positive dynamics of the main markers of the lipid profile, and a reduce in the level of serum markers of systemic inflammation. These delayed effects can apparently be associated with immunomodulatory effects of therapy, including the possible activation of regulatory CD4+CD25+Foxp+ cells, which, according to the literature, have a protective effect in obesity, reducing insulin resistance.

Keywords

allokin / immunomodulatory therapy / inflammation / metabolic syndrome

Cite this article

Download citation ▾

N A Didkovsky, I K Malashenkova, J V Abakumova, D P Ogurtsov, S A Krynskiy, N A Hailov, E I Chekulaeva, M V Mamoshina. THE EFFECTS OF ALLOFERON (ALLOKIN) IN THE THERAPY OF METABOLIC SYNDROME (A PILOT STUDY). Medical academic journal, 2019, 19(1S): 212-215 DOI:

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45.

[2]	Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol. 2012;8(12):743-54.

[3]	de Melo LGP, Nunes SOV, Anderson G, et al. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2017;78:34-50.

[4]	Van Herck MA, Weyler J, Kwanten WJ, et al. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Front Immunol. 2019;10:82.

[5]	Francisco V, Pino J, Campos-Cabaleiro V, et al. Obesity, Fat Mass and Immune System: Role for Leptin. Front Physiol. 2018;9:640.

[6]	Scheithauer TP, Dallinga-Thie GM, de Vos WM, et al. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol Metab. 2016;5(9):759-70.

[7]	Sobieszczyk ME, Werner L, Mlisana K, et al. Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune Defic Syndr. 2016; 73(4): 438-445.